Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography.

[1]  C. Voermans,et al.  Remnant Cholesterol Elicits Arterial Wall Inflammation and a Multilevel Cellular Immune Response in Humans , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[2]  D. Berman,et al.  Long-term prognostic impact of CT-Leaman score in patients with non-obstructive CAD: Results from the COronary CT Angiography EvaluatioN For Clinical Outcomes InteRnational Multicenter (CONFIRM) study. , 2017, International journal of cardiology.

[3]  M. Shao,et al.  Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[4]  J. Borén,et al.  The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity , 2016, Current opinion in lipidology.

[5]  R. Blankstein,et al.  European Society of Cardiology–Recommended Coronary Artery Disease Consortium Pretest Probability Scores More Accurately Predict Obstructive Coronary Disease and Cardiovascular Events Than the Diamond and Forrester Score: The Partners Registry , 2016, Circulation.

[6]  R. D'Agostino,et al.  Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies , 2016, Journal of the American Heart Association.

[7]  B. Nordestgaard,et al.  Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease. , 2016, Clinical chemistry.

[8]  B. Nordestgaard.  Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. , 2016, Circulation research.

[9]  J. Mckenney,et al.  National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. , 2015, Journal of clinical lipidology.

[10]  S. Kihara,et al.  Impact of Remnant Lipoprotein on Coronary Plaque Components. , 2015, Journal of atherosclerosis and thrombosis.

[11]  B. Nordestgaard,et al.  Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population. , 2015, Clinical chemistry.

[12]  J. Mckenney,et al.  National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. , 2015, Journal of clinical lipidology.

[13]  Patrick W Serruys,et al.  Long-term prognostic effect of coronary atherosclerotic burden: validation of the computed tomography-Leaman score. , 2015, Circulation. Cardiovascular imaging.

[14]  I. Meredith,et al.  Superior CT coronary angiography image quality at lower radiation exposure with second generation 320-detector row CT in patients with elevated heart rate: a comparison with first generation 320-detector row CT. , 2014, Cardiovascular diagnosis and therapy.

[15]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[16]  F. Rybicki,et al.  Prognostic Value of Nonobstructive and Obstructive Coronary Artery Disease Detected by Coronary Computed Tomography Angiography to Identify Cardiovascular Events , 2014, Circulation. Cardiovascular imaging.

[17]  A. Gotto,et al.  Residual macrovascular risk in 2013: what have we learned? , 2014, Cardiovascular Diabetology.

[18]  B. Nordestgaard,et al.  Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation , 2013, Circulation.

[19]  B. Nordestgaard,et al.  Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. , 2013, European heart journal.

[20]  H. Marques,et al.  Coronary computed tomography angiography-adapted Leaman score as a tool to noninvasively quantify total coronary atherosclerotic burden , 2013, The International Journal of Cardiovascular Imaging.

[21]  D. Berman,et al.  Relationship of low- and high-density lipoproteins to coronary artery plaque composition by CT angiography. , 2013, Journal of cardiovascular computed tomography.

[22]  B. Nordestgaard,et al.  Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[23]  Markus Abt,et al.  Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[24]  C. Ballantyne,et al.  Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). , 2012, Journal of clinical lipidology.

[25]  D. Waters,et al.  Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy: The Treating to New Targets (TNT) Study , 2012, Circulation.

[26]  William Weintraub,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[27]  Yeung Yam,et al.  Incremental Prognostic Value of Cardiac Computed Tomography in Coronary Artery Disease Using CONFIRM: COroNary Computed Tomography Angiography Evaluation for Clinical Outcomes: An InteRnational Multicenter Registry , 2011, Circulation. Cardiovascular imaging.

[28]  M. Taskinen,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.

[29]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[30]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[31]  H. Furukawa,et al.  Prevalence of non-calcified coronary plaque on 64-slice computed tomography in asymptomatic patients with zero and low coronary artery calcium. , 2010, The Canadian journal of cardiology.

[32]  D. Berman,et al.  SCCT guidelines for the interpretation and reporting of coronary computed tomographic angiography. , 2009, Journal of cardiovascular computed tomography.

[33]  Samia Mora,et al.  Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events , 2008, Circulation.

[34]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[35]  Gabriel P Krestin,et al.  64-slice computed tomography coronary angiography in patients with high, intermediate, or low pretest probability of significant coronary artery disease. , 2007, Journal of the American College of Cardiology.

[36]  D. Berman,et al.  Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. , 2007, Journal of the American College of Cardiology.

[37]  Daniel S Berman,et al.  Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. , 2007, Journal of the American College of Cardiology.

[38]  S. Achenbach,et al.  Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography. , 2006, Journal of the American College of Cardiology.

[39]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[40]  D. B. Zilversmit,et al.  Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. , 1988, Journal of lipid research.

[41]  R. Mahley,et al.  Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. , 1980, The Journal of biological chemistry.

[42]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention , 2016, Atherosclerosis.

[43]  Jennifer G. Robinson,et al.  Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. , 2013, Journal of the American Pharmacists Association : JAPhA.

[44]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[45]  &NA; &NA;,et al.  Practice Guideline , 2020, Encyclopedia of Behavioral Medicine.

[46]  S. Abbara.  SCCT guidelines for performance of coronary computed tomographic angiography: A report of the Society of Cardiovascular Computed Tomography Guidelines Committee , 2010 .

[47]  Michael Miller.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[48]  W. Edwards,et al.  Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. , 1998, Journal of the American College of Cardiology.

[49]  Richard G. Lee,et al.  Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans , 2013, Circulation research.